Improving Our Understanding Of The Long Term Impact Of Wrist And Hip Fracture On Quality Of Life

Published Nov 17, 2012
Kristiansand, Norway - Patients with fragility hip fracture experience a long term negative impact on their health related quality of life (HRQOL). However, for fragility wrist fracture, several studies indicate no long term negative effects on HRQOL. A better understanding of the impact of these fractures on HRQOL will inform health policy and decision making in this area. In a recent study, Comparing 15D and SF-6D performance in fragility wrist and hip fracture patients in a two-year follow-up case control study,” published in Value in Health, the performance of two measures of HRQOL (the 15D and SF-6D) was tested in fragility wrist and hip fracture patients in a two-year follow-up case control study. The study was carried out by Associate Professor Gudrun Rohde, Professor Torbjorn Moum and Professor Glenn Haugeberg. The findings from the study illustrate how fragility wrist fracture can negatively impact HRQOL. The study confirms that hip fracture has a sustained, long term negative effect on self-reported physical and mental health. Furthermore, the data indicate that the 15D seems to be more responsive than the SF-6D when assessing utility and HRQOL in both types of fractures. This study will provide important information for guiding health policy and resource allocation in fracture patients, and for the proper interpretation of studies of health utility and HRQOL.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×